BioPharma Credit (BPCR) Competitors GBX 0.89 +0.01 (+1.14%) (As of 09/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider Trades BPCR vs. ESO, LGT, RIV, SGEM, JEMA, NBMI, JGC, BRIG, FWD, and CLCShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include EPE Special Opportunities (ESO), Lighthouse Group (LGT), River and Mercantile Group (RIV), ScotGems (SGEM), JPMorgan Emerg E, ME & Africa Sec (JEMA), NB Global Monthly Income Fund Ltd GBP (NBMI), Jupiter Green (JGC), BlackRock Income and Growth (BRIG), Forward Partners Group (FWD), and Calculus VCT (CLC). These companies are all part of the "asset management" industry. BioPharma Credit vs. EPE Special Opportunities Lighthouse Group River and Mercantile Group ScotGems JPMorgan Emerg E, ME & Africa Sec NB Global Monthly Income Fund Ltd GBP Jupiter Green BlackRock Income and Growth Forward Partners Group Calculus VCT EPE Special Opportunities (LON:ESO) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership. Do insiders & institutionals believe in ESO or BPCR? 13.6% of EPE Special Opportunities shares are held by institutional investors. Comparatively, 41.1% of BioPharma Credit shares are held by institutional investors. 53.1% of EPE Special Opportunities shares are held by insiders. Comparatively, 6.2% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate ESO or BPCR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EPE Special Opportunities 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABioPharma Credit 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community prefer ESO or BPCR? EPE Special Opportunities received 20 more outperform votes than BioPharma Credit when rated by MarketBeat users. Likewise, 67.97% of users gave EPE Special Opportunities an outperform vote while only 64.62% of users gave BioPharma Credit an outperform vote. CompanyUnderperformOutperformEPE Special OpportunitiesOutperform Votes10467.97% Underperform Votes4932.03% BioPharma CreditOutperform Votes8464.62% Underperform Votes4635.38% Which has more risk & volatility, ESO or BPCR? EPE Special Opportunities has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Which has preferable earnings & valuation, ESO or BPCR? BioPharma Credit has higher revenue and earnings than EPE Special Opportunities. EPE Special Opportunities is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEPE Special Opportunities£3.75M11.33£12.80M-£0.01-15,000.00BioPharma Credit£135.74M0.08£108.45M£0.0811.00 Does the media favor ESO or BPCR? In the previous week, EPE Special Opportunities' average media sentiment score of 1.57 beat BioPharma Credit's score of 0.00 indicating that EPE Special Opportunities is being referred to more favorably in the media. Company Overall Sentiment EPE Special Opportunities Very Positive BioPharma Credit Neutral Is ESO or BPCR more profitable? BioPharma Credit has a net margin of 79.90% compared to EPE Special Opportunities' net margin of -10.57%. BioPharma Credit's return on equity of 8.10% beat EPE Special Opportunities' return on equity.Company Net Margins Return on Equity Return on Assets EPE Special Opportunities-10.57% -0.41% 0.41% BioPharma Credit 79.90%8.10%4.98% SummaryBioPharma Credit beats EPE Special Opportunities on 8 of the 14 factors compared between the two stocks. Ad InvestorPlaceWhy Are Buffett, Bezos, and Musk Fleeing Tech? Here's What To Do Now...The financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumping their tech stocks at a pace we've never seen before. What do they know that's pushing them out? One that Fortune is calling:"The Great Cash Out".Click here to get the details now. Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£10.56M£751.67M£2.72B£1.41BDividend Yield7.54%13.40%4.52%11.73%P/E Ratio11.00771.52429.991,587.56Price / Sales0.0814,403.743,037.08183,132.85Price / Cash1.1980.0349.3132.70Price / Book0.011.711.492.83Net Income£108.45M£52.61M£365.78M£152.60M7 Day Performance-3.51%11.81%7.03%7.36%1 Month Performance-5.17%0.72%1.22%-1.09%1 Year Performance7.06%8.72%12.29%27.00% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESOEPE Special Opportunities0 of 5 stars0.00 / 5 starsGBX 152-4.1%N/A-6.5%£43.06M£3.75M-15,200.00N/APositive NewsHigh Trading VolumeLGTLighthouse Group0 of 5 stars0.00 / 5 starsGBX 33.25flatN/AN/A£42.46M£53.42M18.47156RIVRiver and Mercantile Group0 of 5 stars0.00 / 5 starsGBX 49.40-5.0%N/AN/A£42.40M£74.82M-22.45300High Trading VolumeSGEMScotGems0 of 5 stars0.00 / 5 starsN/AN/AN/A£42.02M£5.07M1,121.43N/AJEMAJPMorgan Emerg E, ME & Africa Sec0 of 5 stars0.00 / 5 starsGBX 102+1.2%N/A-30.2%£41.25M£2.15M3,400.00N/ANBMINB Global Monthly Income Fund Ltd GBP0 of 5 stars0.00 / 5 starsGBX 57.50+2.7%N/A-19.6%£41.02MN/A338.24N/AGap UpJGCJupiter Green0 of 5 stars0.00 / 5 starsGBX 215.81-0.5%N/A+7.2%£40.96M£-9,480,000.00-21,581.00N/APositive NewsBRIGBlackRock Income and Growth0 of 5 stars0.00 / 5 starsGBX 205+0.5%N/A+14.9%£40.73M£2.55M2,277.78N/ADividend IncreaseFWDForward Partners Group0 of 5 stars0.00 / 5 starsN/AN/A+7.3%£39.78M£-22,030,000.00-155.2615High Trading VolumeCLCCalculus VCT0 of 5 stars0.00 / 5 starsGBX 58flatN/AN/A£39.36M£1.53M5,800.00N/A Related Companies and Tools Related Companies: EPE Special Opportunities Alternatives Lighthouse Group Alternatives River and Mercantile Group Alternatives ScotGems Alternatives JPMorgan Emerg E, ME & Africa Sec Alternatives NB Global Monthly Income Fund Ltd GBP Alternatives Jupiter Green Alternatives BlackRock Income and Growth Alternatives Forward Partners Group Alternatives Calculus VCT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:BPCR) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
